George Garibaldi, MD
George Garibaldi, M.D., is a psychiatrist and neuroscientist. He currently serves as the chief medical officer (CMO) of Noema, a clinical stage company developing therapies for neurodevelopmental orphan disorders. From 2019-2020, Dr. Garibaldi was CMO at Neuron23, and he currently serves on the company’s board of directors, as chair of its MedDay Pharma Research and Development Review Committee and as a member of its Immune Brain Checkpoint scientific advisory board.
Dr Garibaldi has more than 20 years of experience in global therapy development and medical affairs at Sandoz/Novartis, Janssen and Roche. Most recently, he served as global head of neurosciences product development at F. Hoffmann La Roche. In this role, Dr. Garibaldi developed Ocrelizumab, an anti-CD20 monoclonal antibody, for the treatment of primary progressive and relapsing remitting multiple sclerosis. He served as the scientific leader of a global team of about 50 psychiatrists and neurologists in the U.S., Europe, and Asia. Throughout his career, Dr. Garibaldi has led the global development and approval of multiple new molecular entities in various indications of psychiatry, neurodegenerative, neuro-immunological and neurodevelopmental diseases. He has published about 100 papers in peer-reviewed journals.
Dr. Garibaldi is the founder and past president of the International Society for CNS Trial Methodology and is currently the chairman of the International Society for CNS Drug Development. From 1990-1994, he was associate professor in the department of psychiatry at Université Paris Nord in France. Dr Garibaldi holds a medical degree (MB BcH) from Cairo University, specialized in psychiatry and child psychiatry at Université René Descartes, psychopharmacology at Pitié-Salpêtrière and biostatistics at the Kremlin Bicêtre in Paris.